A steady increase of product titers and the corresponding change in impurity composition
represent a challenge for development and optimization of antibody production processes …

Mammalian cell expression has become the dominant recombinant protein production
system for clinical applications because of its capacity for post-translational modification and …

The rapid development of high-yielding and robust manufacturing processes for monoclonal
antibodies is an area of significant focus in the biopharmaceutical landscape. Advances in …

Recombinant proteins, such as monoclonal antibodies, are produced in mammalian cell
lines to introduce proper protein folding and post‐translational modifications, which are …

Secreted mammalian proteins require the development of robust protein over‐expression
systems for crystallographic and biophysical studies of protein function. Due to complex …

Sales of monoclonal antibody (mAbs) therapies exceeded
40billionin2010andareexpectedtoreach 70 billion by 2015. The majority of the approved …

IgG1 antibodies produced in Chinese hamster ovary (CHO) cells are heavily α1, 6‐
fucosylated, a modification that reduces antibody‐dependent cellular cytotoxicity (ADCC) …

An efficient rapid protein expression system is crucial to support early drug development.
Transient gene expression is an effective route, and to facilitate the use of the same host …

Transient gene expression (TGE) in animal cell cultures has been used for almost 30 years
to produce milligrams and grams of recombinant proteins, virus-like particles and viral …

One of the main challenges in the development of bioprocesses based on cell transient
expression is the commonly reported reduction of cell specific productivity at increasing cell …